|Articles|November 9, 2021
Pharmacy Clinical Pearl of the Day: Alagille Syndrome
Author(s)Saro Arakelians, PharmD
Approximately 75% of people diagnosed with Alagille syndrome in childhood live to at least 20 years of age.
Advertisement
Clinical Pearl of the Day: Alagille Syndrome
Alagille syndrome is an inherited disorder that closely resembles other forms of liver disease seen in infants and young children.
Insight:
- Alagille syndrome causes liver damage. The liver produces bile to help remove waste from the body. It also helps digest fats and the fat-soluble vitamins A, D, E, and K. The body can use these vitamins only if they are combined with fat from the foods people eat. Bile ducts are the channels that move bile out of the liver.
- If a person does not have enough of these ducts, bile builds up in the liver, which damages liver tissues and ultimately can cause the liver to fail.
- Approximately 75% of people diagnosed with Alagille syndrome in childhood live to at least 20 years of age.
- Causes: Alagille syndrome is related to the JAG1 gene mutation.
- Symptoms include yellowish skin or eyes, itchy skin, delayed growth, hard skin bumps, heart murmur, and changes in the blood vessels.
- Treatment may include medications to increase bile flow (ursodeoxycholic acid), cholestyramine, rifampin, and naltrexone. Also, biliary diversion procedures that can help interrupt the normal bile circulation. Vitamin and special nutrition supplementation to support proper growth and development.
- Infants with Alagille syndrome are given a special formula that helps the small intestine absorb fats. The diet usually is high in calories, calcium, and with vitamins A, D, E, and K, and sometimes zinc.
- Liver transplantation, kidney surgery, and heart surgery may be other alternatives to correct any defects.
Sources:
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
3
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
4
FDA Approves Bosaya and Aukelso, Biosimilars to Reference Denosumab
5